IEO education
European Institute of Oncology

Milan, 27th May 2022

Exploring tumor heterogeneity targeting cancer cell and tumor micro-environment

SCIENTIFIC DIRECTORS
Francesco Ceci - Laura L. Travaini

Introduction

Molecular imaging to identify specific oncological targets, such as prostate cancer, neuroendocrine tumors, or breast cancer is gaining attention. At present, the most promising developments in clinical research are related to the prostate-specific membrane antigen (PSMA). PSMA represents an ideal target both for imaging and therapy, namely in the advanced stages of hormone-resistant prostate cancer as well as in early stages with hormone-sensitive disease.

New molecular targets have recently been identified to explore the tumor-microenviroment, especially towards cancer-associated fibroblasts (CAFs).

In this scenario, radiopharmaceuticals for PET imaging (FAPi PET) have recently been developed. These new tracers consist of small peptide inhibitors targeting the fibroblast activation protein (FAP). Therefore, the study of the tumor micro-environment with molecular imaging, and any future developments as theranostic agents, represents one of the areas of greatest scientific interest in nuclear medicine.

Faculty

Scientific Director

Francesco Ceci
Division of Nuclear Medicine, IEO IRCCS Milan, Italy

Laura L. Travaini
Division of Nuclear Medicine, IEO IRCCS Milan, Italy

Speakers

Valentina Ambrosini
Division of Nuclear Medicine, IRCCS Policlinico of S. Orsola Bologna, Italy

Guido Baroni
Department of Electronics, Information and Bioengineering, Policlinico of Milan, Italy

Sergio Bracarda
Division of Medical Oncology, Hospital of Santa Maria, Terni, Italy

Paolo Castellucci
Division of Nuclear Medicine, IRCCS Policlinico of S. Orsola Bologna, Italy

Giuseppe Curigliano
Division of Medical Oncology and Division of New Drug Development for Innovative Therapies, IEO IRCCS Milan, Italy

Romano Danesi
UO Clinical Pharmacology, Department of Clinical and Sperimental Medicine, University of Pisa, Italy

Nicola Fazio
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO IRCCS Milan, Italy

Frederik Giesel
Division of Nuclear Medicine, University of Dusseldorf, Germany

Andrei Gafita
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, USA

Francesco Mattana
Division of Nuclear Medicine, IEO IRCCS Milan, Italy

Lorenzo Muraglia
Division of Nuclear Medicine, IEO IRCCS Milan, Italy

Salvatore Pece
Unit of Molecular and Digital Pathology, IEO IRCCS Milan, Italy

Giuseppe Petralia
Department of Oncology and Hemato-Oncology, University of Milan, Italy
Division of Radiology, IEO IRCCS Milan, Italy

Mattia Riondato
Division Nucleare Medicine-Radio Pharmaceutical, IRCCS Universitary Policlinico S. Martino, Genova, Italy

Silvia Telo
Neospecialist of Nuclear Medicine, University of Bologna

Stefania Volpe
Division of Radiotherapy, IEO IRCCS Milan, Italy

Programme

Friday, May 27th 2022

9.00 Greatings from IEO Scientific Director and Director of Oncology and Hemato-Oncology Department of Milan's University - R. Orecchia, G. Vago
9.15 Conference Introduction - F. Ceci, L.L. Travaini

Session I: Tumor Heterogeneity in NET and Prostate Cancer
Moderators: F. Ceci, L. L. Travaini

9.30 Overview on novel PET radiopharmaceuticals targeting cancer cells and tumor micro-environment - M. Riondato
9.45 Targeting the somatostatin receptor in Neuroendocrine Tumors. Advances in molecular imaging and peptide-receptor radionuclide therapy - V. Ambrosini, N. Fazio
10.15 Discussion
10.30 Coffee Break
10.45 New therapeutic approaches in prostate cancer. PSMA radioligand therapy vs. new target therapies - S. Bracarda, A. Gafita
11.15 Exploring tumor heterogeneity in prostate cancer with PET imaging and whole-body MRI - P. Castellucci, G. Petralia
11.45 Discussion

Hands-On Session I: reporting PSMA-PET in advanced prostate cancer
Moderators: L. Muraglia

12.00 How to report PSMA-PET in advanced prostate cancer. A survival guide for residents in nuclear medicine - Nuclear Medicine Residents, University of Milan
12.30 Lunch

Session II: Tumor Heterogeneity and Tumor Micro-Enviroment
Moderators: P. Castellucci, S. Bracarda

13.30 Exploring the tumor micro-environment. From genetics and molecular pathology to new drug development - R. Danesi, G. Curigliano
14.00 New approaches in the definition of treatment planning: the role of artificial intelligence and radiomics - S. Volpe, G. Baroni
14.30 Discussion
15.00 Molecular mechanisms in the tumor microenvironment: the role Cancer Associated Fibroblasts - S. Pece
15.30 Imaging the Cancer Associated Fibroblasts with FAPi PET image - F. Giesel
16.00 Discussion

Hands-On Session II: practical introduction to FAPi PET image interpretation
Moderators: F. Mattana

16.15 Let's try to report some FAPi PET. Can we make it? - S. Telo
16.45 Wrap-Up

Registration's fee

Registration is free of charge subject to availability

Certificate of attendance and CME credits

The course is accredited ECM (JUST FOR ITALIAN PARTICIPANTS) for:
Medical Oncology, Nuclear Medicine, Radiology, Radiotherapy, Urology, General Surgery
Provider IEO ID 207-347328
Credits: 6

We remind you that in order to be entitled to ECM training credits it is compulsory to: attend 90% of the training hours, fill in the event evaluation questionnaire, take and pass the learning test.

IEO education
Istituto Europeo di Oncologia

MZ EVENTS

Location
Starhotels Ritz
Via Lazzaro Spallanzani, 40,
20129 Milano

Organising Secretariat
Mz Events srl
Via C. Farini 81 – 20159 Milan
Tel. +39 3421863400
ieoedu.eventi@ieo.it

With the Endorsements of

Aiom
Associazione Italiana di Oncologia Medica

AIMN
Associazione Italiana di Medicina Nucleare ed Imaging Molecolare

GICR
Gruppo Interdisciplinare di Chimica dei Radiofarmaci

SIUrO
Società Italiana di Uro-Oncologia

With an unconditional contribution from

Advanced Accelerator Applications
A Novartis Company

BAYER